WO2022227117A1 - Method for synthesizing vidarabine monophosphate and use thereof - Google Patents

Method for synthesizing vidarabine monophosphate and use thereof Download PDF

Info

Publication number
WO2022227117A1
WO2022227117A1 PCT/CN2021/093193 CN2021093193W WO2022227117A1 WO 2022227117 A1 WO2022227117 A1 WO 2022227117A1 CN 2021093193 W CN2021093193 W CN 2021093193W WO 2022227117 A1 WO2022227117 A1 WO 2022227117A1
Authority
WO
WIPO (PCT)
Prior art keywords
reaction
adenosine monophosphate
synthesizing
monophosphate
compound
Prior art date
Application number
PCT/CN2021/093193
Other languages
French (fr)
Chinese (zh)
Inventor
韩林
黄月娜
王小芳
Original Assignee
海南锦瑞制药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 海南锦瑞制药有限公司 filed Critical 海南锦瑞制药有限公司
Publication of WO2022227117A1 publication Critical patent/WO2022227117A1/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/06Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the invention belongs to the field of drug synthesis, and relates to the synthesis and preparation of an antiviral drug, in particular to a synthesis method and application of adenosine monophosphate arabinoside.
  • Adenosine monophosphate [chemical name: 9-( ⁇ -D-arabinofuranose) adenine 5'-monophosphate, I] is a nucleotide antiviral drug, and its pharmacological effect is to deoxygenate the virus. Binds to ribonucleotide polymerase, reducing its activity and inhibiting DNA synthesis. After adenosine monophosphate enters cells, it undergoes phosphorylation to generate arabinosine diphosphate (Ara-ADP) and arabinosine triphosphate (Ara-ATP).
  • Antiviral activity is mainly caused by arabinosine triphosphate (Ara-ATP), Ara-ATP competes with deoxyadenosine triphosphate (dATP) to bind to viral DNAP, thereby inhibiting enzyme activity and viral DNA synthesis At the same time, it inhibits the activity of viral nucleotide reductase and inhibits the synthesis of viral DNA, and also inhibits the activity of deoxynucleotidyltransferase at the end of viral DNA, so that Ara-ATP penetrates into the viral DNA and is connected to the 3' of the DNA chain.
  • the end of the -OH position inhibits the continued synthesis of viral DNA, and its chemical formula is:
  • Adenosine monophosphate is a water-soluble derivative of vidarabine, which has obvious inhibitory activity against various DNA viruses such as type I and type II herpes simplex virus, herpes zoster virus, chickenpox virus, and vaccinia virus; Adenosine monophosphate is also widely used in the treatment of viral hepatitis B in China.
  • adenosine monophosphate monophosphate is relatively large, and a synthesis process of adenosine monophosphate monophosphate must be available in order to meet the needs of clinical medication.
  • the first synthetic route uses adenosine monophosphate as a raw material to prepare adenosine monophosphate first, and the latter is phosphorylated to obtain adenosine monophosphate:
  • the reaction process includes two processes of dephosphorylation and phosphorylation. The steps are long, the yield is low, and the total yield is only 8%; especially, there are many phosphorylation by-products, which brings difficulties to separation and purification.
  • the second synthetic route uses adenosine monophosphate as a raw material, is protected and then brominated, and then undergoes reactions such as amination, sulfhydrylation, and hydrogenation to obtain monophosphate.
  • Adenosine Phosphate Adenosine Phosphate:
  • the present invention aims to provide a method for synthesizing adenosine monophosphate, so as to shorten the synthesis process of adenosine monophosphate, reduce industrial production costs, and improve the total reaction yield. rate purpose.
  • a synthetic method of adenosine monophosphate comprises the following steps:
  • the organic solvent A is tetrahydrofuran (THF), toluene, N,N-dimethylformamide (DMF) or dimethylsulfoxide (DMSO);
  • the base is carbonate or organic Alkali;
  • the carbonate is sodium carbonate, sodium bicarbonate, potassium carbonate or cesium carbonate;
  • the organic base is triethylamine (TEA) or N,N-diisopropylethylamine (DIPEA);
  • the catalyst is tetrakis (triphenylphosphine) palladium or [1,1'-bis (diphenylphosphino) ferrocene] palladium dichloride;
  • the reaction temperature of the condensation reaction is 60-150°C, and the reaction time is 2-10h;
  • the alkaline solvent is ammonia water or a sodium hydroxide solution with a concentration of 40%;
  • the reaction temperature of the epoxidation reaction is 90-120° C., and the reaction time is 8-12 h;
  • the purification treatment I is to adjust the pH to neutrality with 1N hydrochloric acid, then add ethyl acetate for extraction, retain and concentrate the organic phase, until no solvent is evaporated, to obtain compound (5 )Crude;
  • the hydrosulfide is at least one of potassium hydrosulfide, sodium hydrosulfide and hydrosulfide;
  • the organic solvent B is tetrahydrofuran (THF), dichloromethane (DCM) or Trichloromethane;
  • the reaction temperature of the ring-opening reaction is 40-70 °C, and the reaction time is 5-8 h;
  • the purification treatment II is adding dichloromethane for extraction, adding silica gel, concentrating, and performing column Chromatography, the eluent is petroleum ether with a volume ratio of 13 to 19:1: dichloromethane, and the eluent is collected and concentrated to obtain the crude product of compound (6);
  • the lower alcohol is methanol (MeOH) or ethanol (EtOH);
  • the reaction temperature of the desulfurization reaction is 50-90° C., and the reaction time is 2-5 h;
  • the present invention also provides an application of the method for synthesizing adenosine monophosphate, the method for synthesizing adenosine monophosphate is used for synthesizing adenosine monophosphate; the obtained adenosine monophosphate is used for preparing injection with adenosine monophosphate.
  • the present invention has the following beneficial effects:
  • the synthetic method of the adenosine monophosphate monophosphate provided by the present invention adopts the small molecule condensation to make the intermediate of monophosphate vidarabine, shortens the process route, simplifies the synthesis steps, and saves the protection group The introduction of , to avoid the formation of other side reactions;
  • the method for synthesizing adenosine monophosphate monophosphate provided by the present invention improves the total reaction yield of synthesizing adenosine monophosphate arabinophosphate because the synthesis steps are simplified, thereby indirectly reducing the industrial production cost.
  • the adenosine monophosphate synthesized by the synthetic method of adenosine monophosphate provided by the present invention can not only be used for the preparation of adenosine monophosphate for injection, but also can be prepared into various dosage forms, such as , sprays, ointments, etc., can avoid the local pain and other symptoms caused by adenosine monophosphate injection.
  • the method for synthesizing adenosine monophosphate arabinoside provided by the present invention further simplifies the industrial production steps, improves the overall reaction yield, and reduces the industrial production cost.
  • the invention is suitable for synthesizing adenosine monophosphate monophosphate, and the synthesized adenosine monophosphate monophosphate is used for preparing adenosine monophosphate monophosphate for injection.
  • Fig. 1 is the HPLC chart of the adenosine monophosphate arabinoside synthesized in Example 1 of the present invention.
  • Embodiment 1 A kind of synthetic method of adenosine monophosphate M1
  • the present embodiment provides a method for synthesizing adenosine monophosphate M1, which comprises the following steps:
  • Embodiment 2 ⁇ 6 The synthetic method of adenosine monophosphate M2 ⁇ M6
  • Embodiments 2 to 6 provide the synthesis methods of adenosine monophosphate M2 to M6, and the synthesis method is roughly the same as the synthesis method of adenosine monophosphate monophosphate provided in Example 1, and the difference is only that some synthetic process parameters are different. , the specific synthesis process parameters are shown in Table 1.
  • the synthetic method of adenosine monophosphate D1 provided by this comparative example is basically the same as that of Example 1, except that the condensation reaction temperature is 55°C, the reaction is performed for 13 hours, and the reaction progress is monitored by TLC, and the ultraviolet point of the raw material (2) is still there Residual, continue to keep stirring for 3h, TLC monitoring still has raw material (2) remaining, finish the reaction, handle according to the processing mode in Example 1, obtain 17.69g compound (4) (yield is 33%), continue to follow Example 1
  • the methods in steps 2) to 4) synthesize arabinosine monophosphate, and the obtained arabinosine monophosphate D1 is 4.55 g (the total yield is 13.1%, and the purity is 98.7%).
  • the synthetic method of adenosine monophosphate D2 provided by this comparative example is basically the same as that of Example 1, the difference is only that the condensation reaction temperature is 155 ° C, the reaction is performed for 6 h, the progress of the reaction is monitored by TLC, and the ultraviolet point of the raw material (2) disappears, Take a small amount of reaction solution and do liquid chromatograph detection, and compared with the compound (4) obtained in step 1) in Example 1, the polarity is larger than that of compound (4), the molecular weight is 559, and the obtained molecular formula is:
  • the synthetic method of adenosine monophosphate D3 provided in this comparative example is basically the same as that of Example 1, except that the epoxidation reaction temperature is 80 °C, the reaction is performed for 15 h, the reaction progress is monitored by TLC, and the ultraviolet point of compound (4) Exist, no new point is generated, continue to keep stirring for 2h, TLC monitoring still no new point is generated, that is, the synthesis fails.
  • the synthetic method of adenosine monophosphate D4 provided in this comparative example is basically the same as that of Example 1, except that the epoxidation reaction temperature is 130 ° C, the reaction is performed for 15 h, the reaction progress is monitored by TLC, and the ultraviolet point of compound (4) Disappeared, a new point was generated, and the sample was injected into the liquid chromatograph.
  • the obtained material had a higher peak polarity and a molecular weight of 265.
  • the molecular formula was:
  • the synthetic method of adenosine monophosphate D5 provided in this comparative example is basically the same as that of Example 1, the difference is only that the temperature of the ring-opening reaction is room temperature, the reaction is performed for 10 h, the progress of the reaction is monitored by TLC, and the ultraviolet point of compound (5) exists, No new spots were generated, and the temperature was kept stirring for 5 h. If no new spots were generated by TLC monitoring, the synthesis failed.
  • the synthetic method of adenosine monophosphate D6 provided in this comparative example is basically the same as that of Example 1, the difference is that the temperature of the ring-opening reaction is 80 °C, the reaction is performed for 5 h, the progress of the reaction is monitored by TLC, and the ultraviolet point of compound (5) disappears , a new point is generated, which is quite different from compound (6) in polarity.
  • the molecular weight measured by sampling and sending to the liquid phase is 413, and the molecular formula is:
  • the synthetic method of adenosine monophosphate D7 provided by this comparative example is basically the same as that of Example 1, the difference is only that the eluent used in step 4) is a mixed solution of petroleum ether with a volume ratio of 10:1: dichloromethane Elution, all impurities were eluted together with adenosine monophosphate D7, which could not achieve the purpose of separation by column chromatography.
  • the obtained arabinosine monophosphate D7 8.79g (yield 93%; purity 90.6%) .
  • the synthetic method of adenosine monophosphate D8 provided by this comparative example is basically the same as that of Example 1, except that the eluent used in step 4) is a mixed solution of petroleum ether with a volume ratio of 22:1: dichloromethane
  • adenosine monophosphate D8 still could not be eluted, and the separation purpose of column chromatography could not be achieved.
  • the polarity of the eluent was gradually increased to 19:1, and adenosine monophosphate was eluted.
  • the obtained Adenosine monophosphate D8 6.99 g (74% yield; 20.17% overall yield; 95.3% purity).
  • This comparative example adopts the Chinese invention patent whose application number is 200410015563.4 to synthesize adenosine monophosphate D9, and the method steps are:
  • reaction kettle 60 grams of IV was suspended in 300 ml of ethanol, and ammonia gas was passed through to saturation at 0 to 5 °C, and the reaction was stirred at 65 to 70 °C for 20 hours after sealing. After cooling to room temperature, the steel kettle was placed in a dry ice-methanol bath (or ice-salt bath) for 2 hours. The precipitated solid was collected by filtration and washed with cold methanol to obtain 35 g of V, which could be used for the next reaction.
  • the freeze-drying box pre-freeze at -50°C for 2 hours, vacuumize the box to 25Pa, slowly raise the temperature at 2°C/hour for sublimation until the product temperature reaches -5°C, further heat up for desorption drying, equilibrate at 40°C for 1 hour, Press the full stopper.
  • the freeze-dried products are crimped, inspected by light, labelled and packaged.
  • Adenosine monophosphate for injection prepared in the above application example was placed under the conditions of temperature 40 °C ⁇ 2 °C and relative humidity 75% ⁇ 5% for 6 months, after sampling analysis, the analysis results of each index were consistent with 0. Compared with the previous month, the content decreased slightly, and the related substances increased slightly, but they were all within the proposed limits, and other test indicators did not change significantly. The lower quality is basically stable, and the measurement results are shown in Table 2.
  • the adenosine monophosphate for injection prepared in the above application example was placed for 24 months under the conditions of a temperature of 25 ° C ⁇ 2 ° C and a relative humidity of 60 ⁇ 10%. After sampling and analysis, the analysis results of various indicators were the same as Compared with 0 months, the content decreased slightly and the related substances increased slightly, but they were all within the proposed limits. There was no significant change in other monitoring indicators, indicating that the quality of this product was basically stable under the conditions of long-term testing. The test results are shown in Table 3. .
  • the validity period of this product can be tentatively set to 24 months.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Saccharide Compounds (AREA)

Abstract

Disclosed are a method for synthesizing vidarabine monophosphate and the use thereof, which belong to the field of drug synthesis. The synthesis method comprises subjecting 5-iodo-2-((phosphonooxy)methyl)-4-(tosyloxy)tetrahydrofuran-3-yl acetate and tert-butyl(8-hydroxy-9H-purin-6-yl)carbamate to condensation, epoxidation, ring opening and desulfurization reactions in order to synthesize vidarabine monophosphate. The provided method for synthesizing vidarabine monophosphate further simplifies the industrial production steps, improves the total reaction yield, and reduces the industrial production cost. The synthesis method is suitable for the synthesis of vidarabine monophosphate, and the synthesized vidarabine monophosphate is used for preparing vidarabine monophosphate for injection.

Description

单磷酸阿糖腺苷的合成方法及应用Synthetic method and application of adenosine monophosphate arabinoside 技术领域technical field
本发明属于药物合成领域,涉及一种抗病毒药物的合成制备,具体地说是一种单磷酸阿糖腺苷的合成方法及应用。The invention belongs to the field of drug synthesis, and relates to the synthesis and preparation of an antiviral drug, in particular to a synthesis method and application of adenosine monophosphate arabinoside.
背景技术Background technique
单磷酸阿糖腺苷【化学名为:9-(β-D-阿拉伯呋喃糖)腺嘌呤5’-单磷酸酯,I】为核苷酸类抗病毒药物,其药理作用是与病毒的脱氧核糖核苷酸聚合酶结合,使其活性降低而抑制DNA合成。单磷酸阿糖腺苷进入细胞后,经过磷酸化生成阿糖腺苷二磷酸(Ara-ADP)和阿糖腺苷三磷酸(Ara-ATP)。抗病毒活性主要由阿糖腺苷三磷酸(Ara-ATP)所引起,Ara-ATP与脱氧腺苷三磷酸(dATP)竞争地结合到病毒DNAP上,从而抑制了酶的活性及病毒DNA的合成,同时抑制病毒核苷酸还原酶的活性而抑制病毒DNA的合成,还能抑制病毒DNA末端脱氧核苷酰转移酶的活性,使Ara-ATP渗入到病毒的DNA中并连接在DNA链3’-OH位置的末端,抑制了病毒DNA的继续合成,其化学式为:Adenosine monophosphate [chemical name: 9-(β-D-arabinofuranose) adenine 5'-monophosphate, I] is a nucleotide antiviral drug, and its pharmacological effect is to deoxygenate the virus. Binds to ribonucleotide polymerase, reducing its activity and inhibiting DNA synthesis. After adenosine monophosphate enters cells, it undergoes phosphorylation to generate arabinosine diphosphate (Ara-ADP) and arabinosine triphosphate (Ara-ATP). Antiviral activity is mainly caused by arabinosine triphosphate (Ara-ATP), Ara-ATP competes with deoxyadenosine triphosphate (dATP) to bind to viral DNAP, thereby inhibiting enzyme activity and viral DNA synthesis At the same time, it inhibits the activity of viral nucleotide reductase and inhibits the synthesis of viral DNA, and also inhibits the activity of deoxynucleotidyltransferase at the end of viral DNA, so that Ara-ATP penetrates into the viral DNA and is connected to the 3' of the DNA chain. The end of the -OH position inhibits the continued synthesis of viral DNA, and its chemical formula is:
Figure PCTCN2021093193-appb-000001
Figure PCTCN2021093193-appb-000001
单磷酸阿糖腺苷是阿糖腺苷的水溶性衍生物,对各种DNA病毒如I型和II型单纯性疱疹病毒、带状疱疹病毒、水痘病毒、牛痘病毒都有明显的抑制活性;在中国,单磷酸阿糖腺苷还广泛用于治疗病毒性乙型肝炎。Adenosine monophosphate is a water-soluble derivative of vidarabine, which has obvious inhibitory activity against various DNA viruses such as type I and type II herpes simplex virus, herpes zoster virus, chickenpox virus, and vaccinia virus; Adenosine monophosphate is also widely used in the treatment of viral hepatitis B in China.
但是,单磷酸阿糖腺苷临床用药剂量较大,为满足临床用药需要必须具备合适工业生产的单磷酸阿糖腺苷的合成工艺。However, the clinical dosage of adenosine monophosphate monophosphate is relatively large, and a synthesis process of adenosine monophosphate monophosphate must be available in order to meet the needs of clinical medication.
文献报道的化学合成方法主要有两种。There are two main chemical synthesis methods reported in the literature.
第一条合成路线(M.Ikebara,et al.Tetrahedron Let 1972;28:3695.)以单磷酸腺苷为原料,先制备阿糖腺苷,后者经磷酸化得到单磷酸阿糖腺苷:The first synthetic route (M.Ikebara, et al. Tetrahedron Let 1972; 28:3695.) uses adenosine monophosphate as a raw material to prepare adenosine monophosphate first, and the latter is phosphorylated to obtain adenosine monophosphate:
Figure PCTCN2021093193-appb-000002
Figure PCTCN2021093193-appb-000002
反应过程包括脱磷酸和磷酸化两个过程,步骤较长,产率较低,总产量只有8%;特别是磷酸化副产物较多,给分离纯化带来困难。The reaction process includes two processes of dephosphorylation and phosphorylation. The steps are long, the yield is low, and the total yield is only 8%; especially, there are many phosphorylation by-products, which brings difficulties to separation and purification.
第二条合成路线(Masakatsu Kaneko,et al.Chem Pharm Bull 1977;25:1892.)以单磷酸腺苷为原料,经保护后溴化,再经氨化、巯基化、氢化等反应,得到单磷酸阿糖腺苷:The second synthetic route (Masakatsu Kaneko, et al.Chem Pharm Bull 1977; 25:1892.) uses adenosine monophosphate as a raw material, is protected and then brominated, and then undergoes reactions such as amination, sulfhydrylation, and hydrogenation to obtain monophosphate. Adenosine Phosphate:
Figure PCTCN2021093193-appb-000003
Figure PCTCN2021093193-appb-000003
此工艺整个过程无需脱磷酸和磷酸化,总产率可达到12%。但是大部分中间体及最终产品需用活性碳亲和层析和离子交换树脂层析分离,而且反应涉及多次保护和脱保护,不利于工业化生产。The whole process of this process does not require dephosphorylation and phosphorylation, and the total yield can reach 12%. However, most of the intermediates and final products need to be separated by activated carbon affinity chromatography and ion exchange resin chromatography, and the reaction involves multiple protection and deprotection, which is not conducive to industrial production.
发明内容SUMMARY OF THE INVENTION
为解决现有技术中存在的以上不足,本发明旨在提供一种单磷酸阿糖腺苷的合成方法,以达到缩短单磷酸阿糖腺苷的合成工艺,降低工业生产成本,提高总反应收率的目的。In order to solve the above deficiencies in the prior art, the present invention aims to provide a method for synthesizing adenosine monophosphate, so as to shorten the synthesis process of adenosine monophosphate, reduce industrial production costs, and improve the total reaction yield. rate purpose.
为实现上述目的,本发明所采用的技术方案如下:For achieving the above object, the technical scheme adopted in the present invention is as follows:
一种单磷酸阿糖腺苷的合成方法,所述合成方法包括以下步骤:A synthetic method of adenosine monophosphate, the synthetic method comprises the following steps:
1)取5-碘-2-((磷羧基氧代)甲基)-4-(甲苯磺酰氧代)四氢呋喃-3-基乙酸酯(2)与叔-丁基(8-羟基-9H-嘌呤-6-基)氨基甲酸酯(3)混于有机溶剂A中,加入碱和钯催化剂进行缩合反应,经过滤浓缩后,得到化合物(4)粗品;1) Take 5-iodo-2-((phosphorus carboxy)methyl)-4-(toluenesulfonyl oxo)tetrahydrofuran-3-yl acetate (2) and tert-butyl(8-hydroxy- 9H-purin-6-yl) carbamate (3) is mixed in organic solvent A, add alkali and palladium catalyst to carry out condensation reaction, after filtration and concentration, obtain compound (4) crude product;
2)取化合物(4)粗品溶于THF,再加入碱性溶剂,进行环氧化反应,反应结束后,进行纯化处理I,得到化合物(5)粗品;2) get the crude product of compound (4) and dissolve it in THF, then add an alkaline solvent to carry out epoxidation reaction, and after the reaction finishes, carry out purification treatment 1 to obtain the crude product of compound (5);
3)取化合物(5)粗品与硫氢化物在有机溶剂B中混合,进行开环反应,反应结束后,进行纯化处理II,得到化合物(6)粗品;3) get compound (5) crude product and mix in organic solvent B with hydrosulfide, carry out ring-opening reaction, after the reaction finishes, carry out purification treatment II, obtain compound (6) crude product;
4)取化合物(6)粗品溶于低级醇,加入雷尼镍进行脱硫反应,即得单磷酸阿糖腺苷(1),其总反应式为:4) get compound (6) crude product and be dissolved in lower alcohol, add Raney nickel to carry out desulfurization reaction, promptly obtain monophosphate adenosine arabinophosphate (1), and its total reaction formula is:
Figure PCTCN2021093193-appb-000004
Figure PCTCN2021093193-appb-000004
作为本发明的限定,所述有机溶剂A为四氢呋喃(THF)、甲苯、N,N-二甲基甲酰胺(DMF)或二甲基亚砜(DMSO);所述碱为碳酸盐或有机碱;所述碳酸盐为碳酸钠、碳酸氢钠、碳酸钾或碳酸铯;所述有机碱为三乙胺(TEA)或N,N-二异丙基乙胺(DIPEA);所述钯催化剂为四(三苯基膦)钯或[1,1'-双(二苯基膦基)二茂铁]二氯化钯;As a limitation of the present invention, the organic solvent A is tetrahydrofuran (THF), toluene, N,N-dimethylformamide (DMF) or dimethylsulfoxide (DMSO); the base is carbonate or organic Alkali; the carbonate is sodium carbonate, sodium bicarbonate, potassium carbonate or cesium carbonate; the organic base is triethylamine (TEA) or N,N-diisopropylethylamine (DIPEA); the palladium The catalyst is tetrakis (triphenylphosphine) palladium or [1,1'-bis (diphenylphosphino) ferrocene] palladium dichloride;
作为本发明的另一种限定,所述缩合反应的反应温度为60~150℃、反应时间为2~10h;As another limitation of the present invention, the reaction temperature of the condensation reaction is 60-150°C, and the reaction time is 2-10h;
作为本发明的第三种限定,所述碱性溶剂为氨水或浓度为40%的氢氧化钠溶液;所述环氧化反应的反应温度为90~120℃、反应时间为8~12h;As the third limitation of the present invention, the alkaline solvent is ammonia water or a sodium hydroxide solution with a concentration of 40%; the reaction temperature of the epoxidation reaction is 90-120° C., and the reaction time is 8-12 h;
作为本发明的第四种限定,所述纯化处理I为用1N的盐酸调节pH至中性,再加入乙酸乙酯萃取,保留并浓缩有机相,直至再无溶剂蒸出,即得化合物(5)粗品;As the fourth limitation of the present invention, the purification treatment I is to adjust the pH to neutrality with 1N hydrochloric acid, then add ethyl acetate for extraction, retain and concentrate the organic phase, until no solvent is evaporated, to obtain compound (5 )Crude;
作为本发明的第五种限定,所述硫氢化物为硫氢化钾、硫氢化钠和硫氢酸中的至少一种;所述有机溶剂B为四氢呋喃(THF)、二氯甲烷(DCM)或三氯甲烷;As the fifth limitation of the present invention, the hydrosulfide is at least one of potassium hydrosulfide, sodium hydrosulfide and hydrosulfide; the organic solvent B is tetrahydrofuran (THF), dichloromethane (DCM) or Trichloromethane;
作为本发明的第六种限定,所述开环反应的反应温度为40~70℃、反应时间为5~8h;所述纯化处理II为加入二氯甲烷萃取,并加入硅胶,浓缩,进行柱层析,洗脱剂为体积比为13~19:1的石油醚:二氯甲烷,收集并浓缩洗脱剂,即得化合物(6)粗品;As the sixth limitation of the present invention, the reaction temperature of the ring-opening reaction is 40-70 °C, and the reaction time is 5-8 h; the purification treatment II is adding dichloromethane for extraction, adding silica gel, concentrating, and performing column Chromatography, the eluent is petroleum ether with a volume ratio of 13 to 19:1: dichloromethane, and the eluent is collected and concentrated to obtain the crude product of compound (6);
作为本发明的第七种限定,所述低级醇为甲醇(MeOH)或乙醇(EtOH);所述脱硫反应的反应温度为50~90℃、反应时间为2~5h;As the seventh limitation of the present invention, the lower alcohol is methanol (MeOH) or ethanol (EtOH); the reaction temperature of the desulfurization reaction is 50-90° C., and the reaction time is 2-5 h;
本发明还提供单磷酸阿糖腺苷的合成方法的一种应用,所述单磷酸阿糖腺苷的合成方法用于合成单磷酸阿糖腺苷;所得单磷酸阿糖腺苷用于制备注射用单磷酸阿糖腺苷。The present invention also provides an application of the method for synthesizing adenosine monophosphate, the method for synthesizing adenosine monophosphate is used for synthesizing adenosine monophosphate; the obtained adenosine monophosphate is used for preparing injection with adenosine monophosphate.
由于采用了上述的技术方案,本发明与现有技术相比,所取得的有益效果是:Due to adopting the above-mentioned technical scheme, compared with the prior art, the present invention has the following beneficial effects:
(1)本发明所提供的单磷酸阿糖腺苷的合成方法,采用小分子缩合制成单磷酸阿糖腺苷的中间体,缩短了工艺路线,简化了合成步骤,省去了对保护基的引入,避免其他副反应的生成;(1) the synthetic method of the adenosine monophosphate monophosphate provided by the present invention, adopts the small molecule condensation to make the intermediate of monophosphate vidarabine, shortens the process route, simplifies the synthesis steps, and saves the protection group The introduction of , to avoid the formation of other side reactions;
(2)本发明所提供的单磷酸阿糖腺苷的合成方法,由于简化了合成步骤,提高了合成单磷酸阿糖腺苷的总反应收率,间接减少了工业生产成本。(2) The method for synthesizing adenosine monophosphate monophosphate provided by the present invention improves the total reaction yield of synthesizing adenosine monophosphate arabinophosphate because the synthesis steps are simplified, thereby indirectly reducing the industrial production cost.
(3)本发明所提供的单磷酸阿糖腺苷的合成方法所合成的单磷酸阿糖腺苷,不仅可以用于制备注射用单磷酸阿糖腺苷,还可以制备成多种剂型,如,喷雾剂、软膏剂等,可以避免了单磷酸阿糖腺苷注射后,所产生的局部疼痛等症状。(3) The adenosine monophosphate synthesized by the synthetic method of adenosine monophosphate provided by the present invention can not only be used for the preparation of adenosine monophosphate for injection, but also can be prepared into various dosage forms, such as , sprays, ointments, etc., can avoid the local pain and other symptoms caused by adenosine monophosphate injection.
综上所述,本发明所提供的单磷酸阿糖腺苷的合成方法,进一步简化了工业生产步骤,提高了总的反应收率,减少了工业生产成本。To sum up, the method for synthesizing adenosine monophosphate arabinoside provided by the present invention further simplifies the industrial production steps, improves the overall reaction yield, and reduces the industrial production cost.
本发明适用于合成单磷酸阿糖腺苷,所合成的单磷酸阿糖腺苷用于制备注射用单磷酸阿糖腺苷。The invention is suitable for synthesizing adenosine monophosphate monophosphate, and the synthesized adenosine monophosphate monophosphate is used for preparing adenosine monophosphate monophosphate for injection.
附图说明Description of drawings
下面结合附图及具体实施例对本发明作更进一步详细说明。The present invention will be described in further detail below in conjunction with the accompanying drawings and specific embodiments.
图1为本发明实施例1所合成的单磷酸阿糖腺苷的HPLC图。Fig. 1 is the HPLC chart of the adenosine monophosphate arabinoside synthesized in Example 1 of the present invention.
具体实施方式Detailed ways
以下结合附图对本发明的优选实施例进行说明。应当理解,此处所描述的优选实施例仅用于说明和理解本发明,并不用于限定本发明。The preferred embodiments of the present invention will be described below with reference to the accompanying drawings. It should be understood that the preferred embodiments described herein are only used to illustrate and understand the present invention, but not to limit the present invention.
实施例1 一种单磷酸阿糖腺苷M1的合成方法Embodiment 1 A kind of synthetic method of adenosine monophosphate M1
本实施例提供一种单磷酸阿糖腺苷M1的合成方法,其合成方法包括以下步骤:The present embodiment provides a method for synthesizing adenosine monophosphate M1, which comprises the following steps:
1)称取53.6g 5-碘-2-((磷羧基氧代)甲基)-4-(甲苯磺酰氧代)四氢呋喃-3-基乙酸酯(2)与30g叔-丁基(8-羟基-9H-嘌呤-6-基)氨基甲酸酯(3)混于220ml THF中,加入31.8g碳酸钠和5.78g四(三苯基膦)钯在70℃,进行缩合反应8h,TLC监测反应进度,原料(2)的紫外显色点消失后,即为反应结束。将反应液过滤,滤饼用乙醇洗涤三次,收集滤液并减压浓缩至再无溶剂蒸出,得到39.54g化合物(4)粗品(收率为60%),直接用于下一步,其反应式为:1) Weigh 53.6g of 5-iodo-2-((phosphorus carboxy)methyl)-4-(toluenesulfonyloxo)tetrahydrofuran-3-yl acetate (2) and 30g of tert-butyl ( 8-Hydroxy-9H-purin-6-yl)carbamate (3) was mixed in 220ml of THF, 31.8g of sodium carbonate and 5.78g of tetrakis(triphenylphosphine)palladium were added at 70°C, and a condensation reaction was carried out for 8h, The progress of the reaction was monitored by TLC, and the reaction was completed when the UV color developing point of the raw material (2) disappeared. The reaction solution was filtered, the filter cake was washed three times with ethanol, the filtrate was collected and concentrated under reduced pressure until no solvent was evaporated to obtain 39.54 g of compound (4) crude product (yield was 60%), which was directly used in the next step. for:
Figure PCTCN2021093193-appb-000005
Figure PCTCN2021093193-appb-000005
2)称取39.54g化合物(4)粗品溶于130mlTHF,再加入15ml浓度为40%的氢氧化钠溶液,密封升温至90℃,混合搅拌12h,进行环氧化反应,取少量反应液,稀释后注入液相色谱仪中,化合物(4)的物料峰消失,即为反应终点,用1N的盐酸6ml调节pH至中性(广谱pH试纸测得pH=7),再加入300ml乙酸乙酯萃取三次,保留合并有机相,再浓缩所有溶剂,即得17.09g化合物(5)粗品(收率为64%),其反应式为:2) Weigh 39.54g of compound (4) crude product and dissolve it in 130ml of THF, then add 15ml of sodium hydroxide solution with a concentration of 40%, seal and heat up to 90°C, mix and stir for 12h, carry out epoxidation reaction, take a small amount of reaction solution, dilute After injecting into the liquid chromatograph, the material peak of compound (4) disappears, which is the end point of the reaction, adjust the pH to neutrality with 6ml of 1N hydrochloric acid (measured pH=7 by broad-spectrum pH test paper), and then add 300ml of ethyl acetate Extracted three times, retained the combined organic phase, and concentrated all the solvents to obtain 17.09 g of compound (5) crude product (yield was 64%). The reaction formula is:
Figure PCTCN2021093193-appb-000006
Figure PCTCN2021093193-appb-000006
3)称取17.09g化合物(5)粗品与2.79g硫氢化钠在75mlDCM中溶解,加热到50℃并保温搅拌8h进行开环反应,抽取少量反应液,稀释后注入液相色谱仪,化合物(5)的物料峰消失,即为反应终点,加入50ml饱和硫代硫酸钠水溶液和200ml二氯甲烷萃取五次,收集有机相,浓缩出反应液总量五分之三的溶剂,再加入与反应物总量的重量比为1:1的硅胶,浓缩剩余溶剂,进行柱层析(200~300目硅胶装柱),使用体积比为13:1的石油醚:二氯甲烷的混合溶剂,收集并浓缩洗脱剂,得到10.33g化合物(6)粗品(收率为71%),其反应式为:3) Weigh 17.09g of compound (5) crude product and 2.79g of sodium hydrosulfide to dissolve in 75ml DCM, heat to 50°C and keep stirring for 8h to carry out ring-opening reaction, extract a small amount of reaction solution, inject into liquid chromatograph after dilution, compound ( 5) The material peak disappears, that is, the reaction end point, add 50ml saturated aqueous sodium thiosulfate solution and 200ml dichloromethane for extraction five times, collect the organic phase, concentrate the solvent of three-fifths of the total amount of the reaction solution, then add and react Silica gel with a weight ratio of 1:1 to the total amount of the product was used, concentrated the remaining solvent, carried out column chromatography (200-300 mesh silica gel column), used a mixed solvent of petroleum ether: dichloromethane with a volume ratio of 13:1, collected And the eluent was concentrated to obtain 10.33 g of compound (6) crude product (the yield was 71%), and its reaction formula was:
Figure PCTCN2021093193-appb-000007
Figure PCTCN2021093193-appb-000007
4)称取10.33g化合物(6)粗品溶于50ml MeOH,加入6g雷尼镍在65℃进行脱硫反应3h,抽取少量反应液稀释后,注入液相色谱仪,化合物(6)的物料峰消失,即为反应终点,浓缩所有溶剂,加入120ml饱和碳酸氢钠溶液搅拌至澄清,加入50g活性炭脱色,过滤并水洗滤饼,50℃减压浓缩掉一半水,加入体积比为5:8的丙酮:环己烷的混合溶液搅拌,逐滴加入10ml磷酸至大量固体析出,过滤、烘干,即得7.85g 单磷酸阿糖腺苷M1(1)(收率为83%;总反应收率为22.6%;纯度为99.7%;),其反应式为:4) Weigh 10.33g of the crude product of compound (6) and dissolve it in 50ml of MeOH, add 6g of Raney nickel to carry out a desulfurization reaction at 65°C for 3h, extract a small amount of the reaction solution for dilution, inject it into a liquid chromatograph, and the material peak of compound (6) disappears , which is the end point of the reaction, concentrate all the solvents, add 120ml saturated sodium bicarbonate solution and stir until it becomes clear, add 50g activated carbon for decolorization, filter and wash the filter cake, concentrate half of the water under reduced pressure at 50 °C, add acetone with a volume ratio of 5:8 : The mixed solution of cyclohexane was stirred, 10 ml of phosphoric acid was added dropwise until a large amount of solid was precipitated, filtered and dried to obtain 7.85 g of adenosine monophosphate M1(1) (the yield was 83%; the total reaction yield was 22.6%; the purity is 99.7%; ), and its reaction formula is:
Figure PCTCN2021093193-appb-000008
Figure PCTCN2021093193-appb-000008
取少量单磷酸阿糖腺苷M1,稀释后注入高效液相色谱仪根据《中国药典》四部通则0512进行检测,测定结果如图1所示。Take a small amount of adenosine monophosphate M1, dilute it and inject it into a high performance liquid chromatograph for detection according to the four general chapters of "Chinese Pharmacopoeia" 0512. The measurement results are shown in Figure 1.
实施例2~6 单磷酸阿糖腺苷M2~M6的合成方法 Embodiment 2~6 The synthetic method of adenosine monophosphate M2~M6
实施例2~6提供了单磷酸阿糖腺苷M2~M6的合成方法,其合成方法与实施例1所提供的单磷酸阿糖腺苷的合成方法大致相同,区别仅在于部分合成工艺参数不同,具体合成工艺参数见表1。 Embodiments 2 to 6 provide the synthesis methods of adenosine monophosphate M2 to M6, and the synthesis method is roughly the same as the synthesis method of adenosine monophosphate monophosphate provided in Example 1, and the difference is only that some synthetic process parameters are different. , the specific synthesis process parameters are shown in Table 1.
表1:单磷酸阿糖腺苷M2~M6的合成工艺参数表Table 1: Synthesis process parameters of adenosine monophosphate M2~M6
Figure PCTCN2021093193-appb-000009
Figure PCTCN2021093193-appb-000009
Figure PCTCN2021093193-appb-000010
Figure PCTCN2021093193-appb-000010
其余工艺参数均与实施例1相同。The rest of the process parameters are the same as in Example 1.
对比例1 单磷酸阿糖腺苷D1的合成方法Comparative Example 1 Synthetic method of adenosine monophosphate D1
本对比例所提供的单磷酸阿糖腺苷D1的合成方法与实施例1基本相同,区别仅在于缩合反应温度为55℃,反应13h,TLC监测反应进度,原料(2)的紫外点仍有残留,继续保温搅拌3h,TLC监测仍有原料(2)残留,结束反应,按照实施例1中的处理方式处理,得到17.69g化合物(4)(收率为33%),继续按照实施例1步骤2)~4)中的方法合成单磷酸阿糖腺苷,所得单磷酸阿糖腺苷D1 4.55g(总收率为13.1%,纯度为98.7%)。The synthetic method of adenosine monophosphate D1 provided by this comparative example is basically the same as that of Example 1, except that the condensation reaction temperature is 55°C, the reaction is performed for 13 hours, and the reaction progress is monitored by TLC, and the ultraviolet point of the raw material (2) is still there Residual, continue to keep stirring for 3h, TLC monitoring still has raw material (2) remaining, finish the reaction, handle according to the processing mode in Example 1, obtain 17.69g compound (4) (yield is 33%), continue to follow Example 1 The methods in steps 2) to 4) synthesize arabinosine monophosphate, and the obtained arabinosine monophosphate D1 is 4.55 g (the total yield is 13.1%, and the purity is 98.7%).
对比例2 单磷酸阿糖腺苷D2的合成方法Comparative Example 2 Synthetic method of adenosine monophosphate D2
本对比例所提供的单磷酸阿糖腺苷D2的合成方法与实施例1基本相同,区别仅在于缩合反应温度为155℃,反应6h,TLC监测反应进度,原料(2)的紫外点消失,取少量反应液做液相色谱仪检测,与实施例1中步骤1)所得化合物(4)对比,极性较化合物(4)大,分子量为559,所得分子式为:The synthetic method of adenosine monophosphate D2 provided by this comparative example is basically the same as that of Example 1, the difference is only that the condensation reaction temperature is 155 ° C, the reaction is performed for 6 h, the progress of the reaction is monitored by TLC, and the ultraviolet point of the raw material (2) disappears, Take a small amount of reaction solution and do liquid chromatograph detection, and compared with the compound (4) obtained in step 1) in Example 1, the polarity is larger than that of compound (4), the molecular weight is 559, and the obtained molecular formula is:
Figure PCTCN2021093193-appb-000011
无化合物(4)生成,即合成失败。
Figure PCTCN2021093193-appb-000011
No compound (4) was produced, that is, the synthesis failed.
对比例3 单磷酸阿糖腺苷D3的合成方法Comparative Example 3 Synthetic method of adenosine monophosphate D3
本对比例所提供的单磷酸阿糖腺苷D3的合成方法与实施例1基本相同,区别仅在于环氧化反应温度为80℃,反应15h,TLC监测反应进度,化合物(4)的紫外点存在,无新点产生,继续保温搅拌2h,TLC监测仍是没有新点产生,即合成失败。The synthetic method of adenosine monophosphate D3 provided in this comparative example is basically the same as that of Example 1, except that the epoxidation reaction temperature is 80 °C, the reaction is performed for 15 h, the reaction progress is monitored by TLC, and the ultraviolet point of compound (4) Exist, no new point is generated, continue to keep stirring for 2h, TLC monitoring still no new point is generated, that is, the synthesis fails.
对比例4 单磷酸阿糖腺苷D4的合成方法Comparative example 4 Synthesis method of adenosine monophosphate D4
本对比例所提供的单磷酸阿糖腺苷D4的合成方法与实施例1基本相同,区别仅在于环氧化反应温度为130℃,反应15h,TLC监测反应进度,化合物(4)的紫外点消失,产生新点,取样注入液相色谱仪中,得到的物料峰极性较大且分子量为265,分子式为:The synthetic method of adenosine monophosphate D4 provided in this comparative example is basically the same as that of Example 1, except that the epoxidation reaction temperature is 130 ° C, the reaction is performed for 15 h, the reaction progress is monitored by TLC, and the ultraviolet point of compound (4) Disappeared, a new point was generated, and the sample was injected into the liquid chromatograph. The obtained material had a higher peak polarity and a molecular weight of 265. The molecular formula was:
Figure PCTCN2021093193-appb-000012
无化合物(5)生成,即合成失败。
Figure PCTCN2021093193-appb-000012
No compound (5) was produced, that is, the synthesis failed.
对比例5 单磷酸阿糖腺苷D5的合成方法Comparative Example 5 Synthetic method of adenosine monophosphate D5
本对比例所提供的单磷酸阿糖腺苷D5的合成方法与实施例1基本相同,区别仅在于开环反应温度为室温,反应10h,TLC监测反应进度,化合物(5)的紫外点存在,无新点产生,继续保温搅拌5h,TLC监测仍是没有新点产生,即合成失败。The synthetic method of adenosine monophosphate D5 provided in this comparative example is basically the same as that of Example 1, the difference is only that the temperature of the ring-opening reaction is room temperature, the reaction is performed for 10 h, the progress of the reaction is monitored by TLC, and the ultraviolet point of compound (5) exists, No new spots were generated, and the temperature was kept stirring for 5 h. If no new spots were generated by TLC monitoring, the synthesis failed.
对比例6 单磷酸阿糖腺苷D6的合成方法The synthetic method of comparative example 6 adenosine monophosphate D6
本对比例所提供的单磷酸阿糖腺苷D6的合成方法与实施例1基本相同,区别仅在于开环反应温度为80℃,反应5h,TLC监测反应进度,化合物(5)的紫外点消失,产生新点,与化合物(6)极性相差较大,取样送液相测得分子量为413,分子式为:The synthetic method of adenosine monophosphate D6 provided in this comparative example is basically the same as that of Example 1, the difference is that the temperature of the ring-opening reaction is 80 °C, the reaction is performed for 5 h, the progress of the reaction is monitored by TLC, and the ultraviolet point of compound (5) disappears , a new point is generated, which is quite different from compound (6) in polarity. The molecular weight measured by sampling and sending to the liquid phase is 413, and the molecular formula is:
Figure PCTCN2021093193-appb-000013
无化合物(6)产生,即为合成失败。
Figure PCTCN2021093193-appb-000013
If no compound (6) is produced, the synthesis fails.
对比例7 单磷酸阿糖腺苷D7的合成方法The synthetic method of comparative example 7 adenosine monophosphate D7
本对比例所提供的单磷酸阿糖腺苷D7的合成方法与实施例1基本相同,区别仅在于步骤4)所用洗脱剂为体积比为10:1的石油醚:二氯甲烷的混合溶液洗脱,所有杂质混合单磷酸阿糖腺苷D7一起被洗脱出来,无法到达柱层析的分离目的,所得单磷酸阿糖腺苷D7 8.79g(收率为93%;纯度为90.6%)。The synthetic method of adenosine monophosphate D7 provided by this comparative example is basically the same as that of Example 1, the difference is only that the eluent used in step 4) is a mixed solution of petroleum ether with a volume ratio of 10:1: dichloromethane Elution, all impurities were eluted together with adenosine monophosphate D7, which could not achieve the purpose of separation by column chromatography. The obtained arabinosine monophosphate D7 8.79g (yield 93%; purity 90.6%) .
对比例8 单磷酸阿糖腺苷D8的合成方法Comparative example 8 Synthesis method of adenosine monophosphate D8
本对比例所提供的单磷酸阿糖腺苷D8的合成方法与实施例1基本相同,区别仅在于步骤4)所用洗脱剂为体积比为22:1的石油醚:二氯甲烷的混合溶液洗脱48h,单磷酸阿糖腺苷D8仍无法洗脱出来,无法到达柱层析的分离目的,逐渐加大洗脱剂极性至19:1,洗脱出单磷酸阿糖腺苷,所得单磷酸阿糖腺苷D8 6.99g(收率为74%;总收率为20.17%;纯度为95.3%)。The synthetic method of adenosine monophosphate D8 provided by this comparative example is basically the same as that of Example 1, except that the eluent used in step 4) is a mixed solution of petroleum ether with a volume ratio of 22:1: dichloromethane After 48 hours of elution, adenosine monophosphate D8 still could not be eluted, and the separation purpose of column chromatography could not be achieved. The polarity of the eluent was gradually increased to 19:1, and adenosine monophosphate was eluted. The obtained Adenosine monophosphate D8 6.99 g (74% yield; 20.17% overall yield; 95.3% purity).
对比例9 单磷酸阿糖腺苷D9的合成方法Comparative Example 9 Synthetic method of adenosine monophosphate D9
本对比例采用申请号为200410015563.4的中国发明专利,合成单磷酸阿糖腺苷D9,其方法步骤为:This comparative example adopts the Chinese invention patent whose application number is 200410015563.4 to synthesize adenosine monophosphate D9, and the method steps are:
(一)2-氧-对-甲苯磺酰酯基-5-磷酸腺苷(II)的制备(1) Preparation of 2-oxo-p-toluenesulfonyl ester-5-phosphate adenosine (II)
在150毫升二氧六环和350毫升1当量氢氧化钠的混合溶液中加入34.7克5-AMP;待溶解后,向此溶液中加入22.8克研细的对-甲苯磺酰氯,于0℃搅拌反应15小时后,加入6当量盐酸35毫升,调节pH至4.0。滤集析出的结晶,得46.4克结晶粉末II。Add 34.7 g of 5-AMP to a mixed solution of 150 ml of dioxane and 350 ml of 1N sodium hydroxide; after dissolving, add 22.8 g of finely ground p-toluenesulfonyl chloride to the solution, and stir at 0°C After 15 hours of reaction, 35 ml of 6N hydrochloric acid was added to adjust the pH to 4.0. The precipitated crystals were collected by filtration to obtain 46.4 g of crystalline powder II.
(二)8-溴-2-氧-对-甲苯磺酰酯基-5-磷酸腺苷(III)的制备(2) Preparation of 8-bromo-2-oxo-p-toluenesulfonyl ester-5-phosphate adenosine (III)
在240毫升2M醋酸钠(pH4)溶液中,加入46克II,冷却至0~5℃。然后向此溶液中滴加19毫升溴,保持0-5℃。在此温度下搅拌18小时。在0~5℃,向反应液中加入28克亚硫酸氢钠。搅拌15分钟后,以5当量氢氧化钠调节pH至4.0(约90~100毫升)。减压蒸干,所得固体直接用于下步反应。In 240 ml of 2M sodium acetate (pH4) solution, add 46 g of II, and cool to 0-5°C. To this solution was then added dropwise 19 ml of bromine, maintaining 0-5°C. Stir at this temperature for 18 hours. 28 g of sodium bisulfite was added to the reaction solution at 0 to 5°C. After stirring for 15 minutes, the pH was adjusted to 4.0 with 5N sodium hydroxide (about 90-100 mL). It was evaporated to dryness under reduced pressure, and the obtained solid was directly used in the next reaction.
(三)8-羟基-N,3-二乙酰基-2-氧-对-甲苯磺酰酯基-5-磷酸腺苷(IV)的制备(3) Preparation of 8-hydroxy-N,3-diacetyl-2-oxo-p-toluenesulfonyl ester-5-phosphate adenosine (IV)
在上步反应产物中加入80毫升乙酸和80毫升乙酸酐,搅拌回流反应2小时。冷至室温后,加入60毫升甲醇。蒸干。加入乙醇,蒸干;再加入乙醇,再蒸干。将残留物以尽可能少量的水加热溶解,搅拌下冷却至5℃,放置过夜。过滤,以少量水洗,真空干燥,得60.2克固体。80 ml of acetic acid and 80 ml of acetic anhydride were added to the reaction product of the previous step, and the reaction was stirred and refluxed for 2 hours. After cooling to room temperature, 60 mL of methanol was added. Evaporate dry. Add ethanol and evaporate to dryness; then add ethanol and evaporate to dryness. The residue was dissolved by heating with as little water as possible, cooled to 5°C with stirring, and allowed to stand overnight. Filter, wash with a small amount of water, and vacuum dry to obtain 60.2 g of solid.
(四)5-磷酸8,2-环氧腺苷(V)的制备(4) Preparation of 5-phosphate 8,2-epoxyadenosine (V)
在反应釜中,将60克IV悬浮于300毫升乙醇,在0~5℃通氨气至饱和,密封后于65~70℃搅拌反应20小时。冷至室温后,将钢釜置于干冰-甲醇浴(或冰盐浴)中2小时。滤集析出的固体,以冷甲醇洗,得35克V,可用于下步反应。In the reaction kettle, 60 grams of IV was suspended in 300 ml of ethanol, and ammonia gas was passed through to saturation at 0 to 5 °C, and the reaction was stirred at 65 to 70 °C for 20 hours after sealing. After cooling to room temperature, the steel kettle was placed in a dry ice-methanol bath (or ice-salt bath) for 2 hours. The precipitated solid was collected by filtration and washed with cold methanol to obtain 35 g of V, which could be used for the next reaction.
(五)单磷酸阿糖腺苷(I)的制备(5) Preparation of adenosine monophosphate (I)
将35克V以240毫升吡啶溶解,装于钢釜中,加入5克Dowex 50x4;通干燥的硫化氢至饱和。密封后于95-100℃加热15小时。通氮气赶去过量的硫化氢,将反应液减压浓缩至干。将残留物以600毫升水溶解,滤去不溶物。在滤液中加入20克瑞尼镍,回流反应2.5小时;再补加6克雷尼镍,回流反应0.5小时,再补加4 克雷尼镍,回流反应0.5小时。滤去不溶物,将滤液减压浓缩至200毫升,用37%的盐酸调节pH2.5,加入晶种,搅拌下冷却至5℃,放置过夜。过滤,以少量水洗,真空干燥,得7.2克单磷酸阿糖腺苷(I)白色固体,总反应式为:Dissolve 35 g of V with 240 ml of pyridine, put it in a steel kettle, add 5 g of Dowex 50x4; pass dry hydrogen sulfide to saturation. After sealing, heat at 95-100°C for 15 hours. Excess hydrogen sulfide was driven off by nitrogen, and the reaction solution was concentrated to dryness under reduced pressure. The residue was dissolved in 600 ml of water, and the insoluble matter was filtered off. 20 grams of Raney nickel was added to the filtrate, and the reaction was refluxed for 2.5 hours; 6 grams of Raney nickel was added, and the reaction was refluxed for 0.5 hours, and 4 grams of Raney nickel was added, and the reaction was refluxed for 0.5 hours. The insoluble matter was filtered off, the filtrate was concentrated under reduced pressure to 200 ml, adjusted to pH 2.5 with 37% hydrochloric acid, seed crystals were added, cooled to 5° C. with stirring, and left overnight. Filter, wash with a small amount of water, and vacuum dry to obtain 7.2 grams of adenosine monophosphate (I) white solid, and the total reaction formula is:
Figure PCTCN2021093193-appb-000014
Figure PCTCN2021093193-appb-000014
应用例注射用单磷酸阿糖腺苷的制备方法Application Example Preparation method of adenosine monophosphate monophosphate for injection
单磷酸阿糖腺苷     100gAdenosine monophosphate 100g
甘露醇             40gMannitol 40g
5%氢氧化钠溶液    适量5% sodium hydroxide solution appropriate amount
注射用水加至2000ml制成1000支。Add water for injection to 2000ml to make 1000 sticks.
制法:随机选取实施例5所合成的单磷酸阿糖腺苷M5 100g,甘露醇40g加入1500ml注射用水溶解,调节pH=7,补足注射用水至2000ml,灌装,将灌装合格品置于冻干箱内,-50℃预冻2小时,将箱内抽真空至25Pa,以2℃/小时缓慢升温进行升华至产品温度达-5℃,进一步升温进行解吸干燥,40℃平衡1小时,压全塞。将冻干品轧盖、灯检、贴签、包装。Preparation method: randomly select 100 g of adenosine monophosphate M5 synthesized in Example 5, add 40 g of mannitol to dissolve in 1500 ml of water for injection, adjust pH=7, make up for water for injection to 2000 ml, fill, and place the qualified product in the filling. In the freeze-drying box, pre-freeze at -50°C for 2 hours, vacuumize the box to 25Pa, slowly raise the temperature at 2°C/hour for sublimation until the product temperature reaches -5°C, further heat up for desorption drying, equilibrate at 40°C for 1 hour, Press the full stopper. The freeze-dried products are crimped, inspected by light, labelled and packaged.
实验例注射用单磷酸阿糖腺苷的稳定性测试Experimental Example Stability test of adenosine monophosphate monophosphate for injection
加速试验accelerated test
以上述应用例中所制备的注射用单磷酸阿糖腺苷在温度40℃±2℃、相对湿度75%±5%的条件下放置6个月,经取样分析,各项指标分析结果与0月的比较,含量稍微下降、有关物质稍增加,但均在拟定的限度范围内,其他各项检测指标无明显变化,本品在温度40℃±2℃、相对湿度75%±5%的条件下质量基本稳定,测定结果见表2。Adenosine monophosphate for injection prepared in the above application example was placed under the conditions of temperature 40 ℃ ± 2 ℃ and relative humidity 75% ± 5% for 6 months, after sampling analysis, the analysis results of each index were consistent with 0. Compared with the previous month, the content decreased slightly, and the related substances increased slightly, but they were all within the proposed limits, and other test indicators did not change significantly. The lower quality is basically stable, and the measurement results are shown in Table 2.
表2:注射用单磷酸阿糖腺苷的加速试验结果Table 2: Accelerated test results of adenosine monophosphate for injection
Figure PCTCN2021093193-appb-000015
Figure PCTCN2021093193-appb-000015
长期试验Long term trial
以上述应用例中所制备的注射用单磷酸阿糖腺苷在温度为25℃±2℃、相对湿度为60±10%的条件下放置24个月,经取样分析,各项指标分析结果与0月的比较,含量稍下降、有关物质稍增加,但均符合拟定的限度范围内,其他各项监测指标无明显变化,说明本品在长期试验的条件下质量基本稳定,测试结果见表3。The adenosine monophosphate for injection prepared in the above application example was placed for 24 months under the conditions of a temperature of 25 ° C ± 2 ° C and a relative humidity of 60 ± 10%. After sampling and analysis, the analysis results of various indicators were the same as Compared with 0 months, the content decreased slightly and the related substances increased slightly, but they were all within the proposed limits. There was no significant change in other monitoring indicators, indicating that the quality of this product was basically stable under the conditions of long-term testing. The test results are shown in Table 3. .
表3:注射用单磷酸阿糖腺苷的长期试验结果表Table 3: Long-term test results of adenosine monophosphate for injection
Figure PCTCN2021093193-appb-000016
Figure PCTCN2021093193-appb-000016
根据《药剂学》中有关药品有效期的规定,本品的有效期可暂定为24个月。According to the regulations on the validity period of drugs in "Pharmaceutics", the validity period of this product can be tentatively set to 24 months.
需要说明的是,以上所述仅为本发明的优选实施例而已,并不用于限制本发明,尽管参照上述实施例对本发明进行了详细的说明,对于本领域技术人员来说,其依然可以对上述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包 含在本发明的保护范围之内。It should be noted that the above descriptions are only preferred embodiments of the present invention, and are not intended to limit the present invention. Although the present invention has been described in detail with reference to the above embodiments, those skilled in the art can still The technical solutions described in the above embodiments are modified, or some technical features thereof are equivalently replaced. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included within the protection scope of the present invention.

Claims (9)

  1. 一种单磷酸阿糖腺苷的合成方法,其特征在于:所述合成方法包括以下步骤:A method for synthesizing adenosine monophosphate, characterized in that: the method for synthesizing comprises the following steps:
    1)取5-碘-2-((磷羧基氧代)甲基)-4-(甲苯磺酰氧代)四氢呋喃-3-基乙酸酯(2)与叔-丁基(8-羟基-9H-嘌呤-6-基)氨基甲酸酯(3)混于有机溶剂A中,加入碱和钯催化剂进行缩合反应,经过滤浓缩后,得到化合物(4)粗品;1) Take 5-iodo-2-((phosphorus carboxy)methyl)-4-(toluenesulfonyl oxo)tetrahydrofuran-3-yl acetate (2) and tert-butyl(8-hydroxy- 9H-purin-6-yl) carbamate (3) is mixed in organic solvent A, add alkali and palladium catalyst to carry out condensation reaction, after filtration and concentration, obtain compound (4) crude product;
    2)取化合物(4)粗品溶于四氢呋喃,再加入碱性溶剂进行环氧化反应,反应结束后,进行纯化处理I,得到化合物(5)粗品;2) get compound (4) crude product and dissolve it in tetrahydrofuran, then add basic solvent to carry out epoxidation reaction, after the reaction finishes, carry out purification treatment 1 to obtain compound (5) crude product;
    3)取化合物(5)粗品与硫氢化物在有机溶剂B中混合,进行开环反应,反应结束后,进行纯化处理II,得到化合物(6)粗品;3) get compound (5) crude product and mix in organic solvent B with hydrosulfide, carry out ring-opening reaction, after the reaction finishes, carry out purification treatment II, obtain compound (6) crude product;
    4)取化合物(6)粗品溶于低级醇,加入雷尼镍进行脱硫反应,即得单磷酸阿糖腺苷(1),其总反应式为:4) get compound (6) crude product and be dissolved in lower alcohol, add Raney nickel to carry out desulfurization reaction, promptly obtain monophosphate adenosine arabinophosphate (1), and its total reaction formula is:
    Figure PCTCN2021093193-appb-100001
    Figure PCTCN2021093193-appb-100001
  2. 根据权利要求1所述的单磷酸阿糖腺苷的合成方法,其特征在于:所述有机溶剂A为四氢呋喃、甲苯、N,N-二甲基甲酰胺或二甲基亚砜;所述碱为碳酸盐或有机碱;所述碳酸盐为碳酸钠、碳酸氢钠、碳酸钾或碳酸铯;所述有机碱为三乙胺或N,N-二异丙基乙胺;所述钯催化剂为四三苯基膦钯或[1,1'-双(二苯基膦基)二茂铁]二氯化钯。The method for synthesizing adenosine monophosphate according to claim 1, wherein the organic solvent A is tetrahydrofuran, toluene, N,N-dimethylformamide or dimethyl sulfoxide; the alkali It is carbonate or organic base; the carbonate is sodium carbonate, sodium bicarbonate, potassium carbonate or cesium carbonate; the organic base is triethylamine or N,N-diisopropylethylamine; the palladium The catalyst is tetrakistriphenylphosphine palladium or [1,1'-bis(diphenylphosphino)ferrocene]dichloride palladium.
  3. 根据权利要求1所述的单磷酸阿糖腺苷的合成方法,其特征在于:所述缩合反应 的反应温度为60~150℃、反应时间为2~10h。The method for synthesizing adenosine monophosphate adenosine monophosphate according to claim 1, characterized in that: the reaction temperature of the condensation reaction is 60~150°C, and the reaction time is 2~10h.
  4. 根据权利要求1~3中任意一项所述的单磷酸阿糖腺苷的合成方法,其特征在于:所述碱性溶剂为氨水或浓度为40%的氢氧化钠溶液;所述环氧化反应的反应温度为90~120℃、反应时间为8~12h。The method for synthesizing adenosine monophosphate according to any one of claims 1 to 3, wherein the alkaline solvent is ammonia water or a sodium hydroxide solution with a concentration of 40%; the epoxidation The reaction temperature of the reaction is 90-120° C., and the reaction time is 8-12 h.
  5. 根据权利要求1~3中任意一项所述的单磷酸阿糖腺苷的合成方法,其特征在于:所述纯化处理I为用1N的盐酸调节pH至中性,再加入乙酸乙酯萃取,保留并浓缩有机相,直至再无溶剂蒸出,即得化合物(5)粗品。The method for synthesizing adenosine monophosphate according to any one of claims 1 to 3, wherein the purification treatment I is to adjust pH to neutrality with 1N hydrochloric acid, and then add ethyl acetate for extraction, The organic phase was retained and concentrated until no more solvent was evaporated to obtain the crude product of compound (5).
  6. 根据权利要求1~3中任意一项所述的单磷酸阿糖腺苷的合成方法,其特征在于:所述硫氢化物为硫氰化钾、硫氢化钠和硫氢酸中的至少一种;所述有机溶剂B为四氢呋喃、二氯甲烷或三氯甲烷。The method for synthesizing adenosine monophosphate according to any one of claims 1 to 3, wherein the hydrosulfide is at least one of potassium thiocyanate, sodium hydrosulfide and hydrosulfide ; The organic solvent B is tetrahydrofuran, dichloromethane or chloroform.
  7. 根据权利要求1~3中任意一项所述的单磷酸阿糖腺苷的合成方法,其特征在于:所述开环反应的反应温度为40~70℃、反应时间为5~8h;所述纯化处理II为加入二氯甲烷萃取,并加入与反应物总量的重量比为1~1.5:1的硅胶,浓缩,进行柱层析,洗脱剂为体积比为13~19:1的石油醚:二氯甲烷,收集并浓缩洗脱剂,即得化合物(6)粗品。The method for synthesizing adenosine monophosphate according to any one of claims 1 to 3, characterized in that: the reaction temperature of the ring-opening reaction is 40-70° C., and the reaction time is 5-8 h; Purification treatment II is adding dichloromethane for extraction, adding silica gel with a weight ratio of 1 to 1.5:1 to the total amount of reactants, concentrating, and performing column chromatography, and the eluent is petroleum with a volume ratio of 13 to 19:1. Ether: dichloromethane, collect and concentrate the eluent to obtain the crude product of compound (6).
  8. 根据权利要求1~3中任意一项所述的单磷酸阿糖腺苷的合成方法,其特征在于:所述低级醇为甲醇或乙醇;所述脱硫反应的反应温度为50~90℃、反应时间为2~5h。The method for synthesizing adenosine monophosphate according to any one of claims 1 to 3, wherein the lower alcohol is methanol or ethanol; the reaction temperature of the desulfurization reaction is 50-90° C. The time is 2 to 5h.
  9. 根据权利要求1~8中任意一项所述的单磷酸阿糖腺苷的合成方法的一种应用,其特征在于:所述单磷酸阿糖腺苷的合成方法用于合成单磷酸阿糖腺苷;所得单磷酸阿糖腺苷用于制备注射用单磷酸阿糖腺苷。An application of the method for synthesizing adenosine monophosphate according to any one of claims 1 to 8, wherein the method for synthesizing adenosine monophosphate is used for synthesizing adenosine monophosphate glucoside; the obtained arabinosine monophosphate is used to prepare arabinosine monophosphate for injection.
PCT/CN2021/093193 2021-04-28 2021-05-12 Method for synthesizing vidarabine monophosphate and use thereof WO2022227117A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110464108.6A CN113173957B (en) 2021-04-28 2021-04-28 Synthesis method and application of vidarabine monophosphate
CN202110464108.6 2021-04-28

Publications (1)

Publication Number Publication Date
WO2022227117A1 true WO2022227117A1 (en) 2022-11-03

Family

ID=76926722

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/093193 WO2022227117A1 (en) 2021-04-28 2021-05-12 Method for synthesizing vidarabine monophosphate and use thereof

Country Status (2)

Country Link
CN (1) CN113173957B (en)
WO (1) WO2022227117A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5344591A (en) * 1976-09-29 1978-04-21 Sankyo Co Ltd Preparation of adenine derivatives
US5700666A (en) * 1993-09-28 1997-12-23 Schering Aktiengesellschaft Process for the production of arabinonucleotides
CN1560065A (en) * 2004-03-05 2005-01-05 陈铁钎 Synthesis process of adenosine aose monophosphate
CN107056862A (en) * 2017-03-24 2017-08-18 甘肃成纪生物药业有限公司 A kind of synthetic method of Vidarabine Monophosphate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2701027B1 (en) * 1993-02-01 1997-07-18 Warner Lambert Co IMPROVED SYNTHESIS PROCESS OF 9- (BETA-D-ARABINOFURANOSYL) ADENINE 5'-PHOSPHATE.
PT101422B (en) * 1993-12-06 1997-06-30 Ineti Inst Biotec Q F E Tecnol LIPOSOMAL FORMULATIONS CONTAINING VIDARABINE AND / OR DERIVATIVES, WITH A HIGH THERAPEUTIC INDEX AND PROCESS FOR THEIR PREPARATION
CN103204890B (en) * 2013-02-22 2016-03-09 广东先强药业有限公司 A kind of phosphorylation prepares the method for vidarabine phosphate
CN110407892A (en) * 2019-08-21 2019-11-05 甘肃泰升化工科技有限公司 A kind of preparation method of Vidarabine Monophosphate
CN111057119A (en) * 2019-12-02 2020-04-24 广东京豪生物制药有限公司 Synthesis process of vidarabine monophosphate

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5344591A (en) * 1976-09-29 1978-04-21 Sankyo Co Ltd Preparation of adenine derivatives
US5700666A (en) * 1993-09-28 1997-12-23 Schering Aktiengesellschaft Process for the production of arabinonucleotides
CN1560065A (en) * 2004-03-05 2005-01-05 陈铁钎 Synthesis process of adenosine aose monophosphate
CN107056862A (en) * 2017-03-24 2017-08-18 甘肃成纪生物药业有限公司 A kind of synthetic method of Vidarabine Monophosphate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KANEKO MASAKATSU, M KIMURA, B SHIMIZU, J YANO, M IKEHARA: "Synthesis of 9-(β-D-Arabinofurnaosyl)adenine 5'-Phosphate starting form Adenosine 5'-Phosphate", CHEM.PHARM.BULL., vol. 25, no. 8, 31 August 1977 (1977-08-31), pages 1892 - 1898, XP055981078, DOI: 10.1248/cpb.25.1892 *

Also Published As

Publication number Publication date
CN113173957A (en) 2021-07-27
CN113173957B (en) 2023-10-27

Similar Documents

Publication Publication Date Title
CN110642897B (en) Preparation method of beta-nicotinamide riboside chloride
Horwitz et al. Nucleosides. III. 1-(2'-Deoxy-3', 5'-epoxy-β-D-threo-pentofuranosyl) thymine1, 2
CN112979733B (en) Anti-hepatitis B virus compound and preparation method and application thereof
CN112724180A (en) Preparation method of beta-nicotinamide mononucleotide
CN1172933C (en) Prepn of matrine, oxymatrine and sophoxidine from flavescent sophora root
CN113105516A (en) Photocleavable fluorescent labeling compounds and uses
CN106146560B (en) A kind of refining methd of high-purity phosphoric acid specially azoles amine
WO2022227117A1 (en) Method for synthesizing vidarabine monophosphate and use thereof
CN107793458B (en) Preparation method of vidarabine monophosphate
Kissman et al. The Synthesis of 1-(Aminodeoxy-β-D-ribofuranosyl)-2-pyrimidinones. New 3'-and 5'-Aminonucleosides
WO2023185812A1 (en) Method for preparing acetylated cytosine triphosphate and intermediate thereof
CN109912672B (en) Method for glycosylation of base by taking o-alkynyl phenol ether as leaving group
CN112457365A (en) Functional molecules of targeting protein hydrolysis pathway and preparation and application thereof
CN113880872A (en) Preparation of camptothecin boric acid compound and application of camptothecin boric acid compound in anti-tumor aspect
CN109134429B (en) Phthalazinone compound, preparation method, pharmaceutical composition and application thereof
CN109134569B (en) A kind of production technology of Vidarabine Monophosphate
CN108018323B (en) Preparation method of adenylyl succinic acid or salt
CN102477057A (en) Thio-nicotinamide adenine dinucleotide, intermediates thereof and preparation methods of thio-nicotinamide adenine dinucleotide and intermediates
CN108299316B (en) Anti-influenza virus compound and preparation method and application thereof
CN111808157B (en) Preparation method of adenosine bulk drug
CN114634488B (en) Succinimide esters and methods of making, treating and detecting same
CN114990175B (en) Synthesis method of fucose derivatives
CN108658989B (en) Preparation method and application of cangrelor intermediate
CN101497640B (en) Novel crystal form of clofarabine
CN116640174A (en) Adenosine cyclophosphate and preparation method thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21938590

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21938590

Country of ref document: EP

Kind code of ref document: A1